Compare AROC & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AROC | APLS |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.2B |
| IPO Year | 2007 | 2015 |
| Metric | AROC | APLS |
|---|---|---|
| Price | $36.52 | $41.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 21 |
| Target Price | ★ $40.00 | $33.59 |
| AVG Volume (30 Days) | 1.6M | ★ 62.6M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | 74.29 | ★ 112.50 |
| EPS | ★ 0.41 | 0.15 |
| Revenue | ★ $1,489,818,000.00 | $1,003,782,000.00 |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $5.27 | $18.19 |
| P/E Ratio | ★ $87.98 | $273.60 |
| Revenue Growth | ★ 28.70 | 28.46 |
| 52 Week Low | $21.17 | $16.83 |
| 52 Week High | $40.12 | $41.14 |
| Indicator | AROC | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 84.57 |
| Support Level | $34.68 | $19.29 |
| Resistance Level | $37.33 | $41.14 |
| Average True Range (ATR) | 1.00 | 0.06 |
| MACD | 0.17 | -0.65 |
| Stochastic Oscillator | 74.32 | 58.33 |
Archrock Inc is an energy infrastructure company focused on midstream natural gas compression. It is a provider of natural gas compression services, based on total compression fleet horsepower, to customers across the United States and a supplier of aftermarket services to customers that own compression equipment. The company operates through two segments: contract operations and aftermarket services. The contract operations segment includes designing, sourcing, owning, installing, operating, servicing, repairing, and maintaining its owned fleet of natural gas compression equipment, and generates the maximum revenue. The aftermarket services segment provides operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).